Genelux (GNLX) Net Income towards Common Stockholders (2022 - 2026)
Genelux (GNLX) recorded quarterly Net Income towards Common Stockholders of -$9.0 million in Q1 2026, up 3.08% quarter-over-quarter from -$9.3 million in Q4 2025, and down 17.9% on a YoY basis from -$11.0 million in Q1 2025.
Genelux (GNLX) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Genelux's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$9.0 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 17.9% year-over-year to -$9.0 million; the TTM figure through Mar 2026 stood at -$33.9 million (down 10.59% YoY), while the FY2025 annual figure was -$32.5 million, down 4.86% from the prior year.
- Net Income towards Common Stockholders was -$9.0 million for Q1 2026 at Genelux, up from -$9.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $4.9 million in Q3 2022 to a low of -$9.6 million in Q1 2023.
- Historically, Net Income towards Common Stockholders has averaged -$6.5 million across 5 years, with a median of -$7.6 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 208.88% in 2023, then increased 17.99% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.5 million in 2022, then tumbled by 93.62% to -$6.8 million in 2023, then tumbled by 41.08% to -$9.5 million in 2024, then increased by 2.75% to -$9.3 million in 2025, then gained by 3.08% to -$9.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$9.0 million (Q1 2026), -$9.3 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.00 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Sep 30, 2025 | -8.02 Mn |
| Jun 30, 2025 | -7.57 Mn |
| Mar 31, 2025 | -7.63 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Sep 30, 2024 | -6.72 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | -7.85 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -5.42 Mn |
| Mar 31, 2023 | -9.57 Mn |
| Dec 31, 2022 | -3.50 Mn |
| Sep 30, 2022 | 4.91 Mn |